AdvaMed CEO Says Some Top Agenda Items For the Year Are ‘Taking A Back Seat’ To Address COVID-19
Executive Summary
AdvaMed has had to adjust to the new COVID-19 reality like everyone else. In an exclusive interview with Medtech Insight, the head of the industry group says they are putting some key issues such as user-fee negotiations, anti-kickback legislation and breakthrough technologies reform on the back burner to prioritize dealing with the current crisis.
You may also be interested in...
AdvaMed: Medtech Industry Wants Seat At Biden’s Coronavirus Response Table
The largest medical device lobby group in the US says it’s open to the administration’s decision to invoke the Defense Production Act to boost testing and PPE production, but wants to be consulted on how to implement it.
Spurred On By HHS Policy Shift, AdvaMed Chief Wants LDT Reform In User-Fee Negotiations
The medical device advocacy group plans to include laboratory developed test reform in their upcoming user-fee negotiations with the US FDA.
FDA Makes 2nd Attempt At Virtual MDUFA Public Meeting
For the second time in the past few months the US agency has rescheduled a webcast of a public meeting meant to start MDUFA V user-fee negotiations.